Companies / Incyte Corporation
Incyte Corporation Pipeline
CompanyIncyte is a U.S. multinational pharmaceutical company headquartered in Wilmington, Delaware. The company develops and manufactures prescription biopharmaceutical medicines across oncology, inflammation, and autoimmunity.
Continuously tracked·last revised
Data: CSV·JSON·Browse the trials
Follow Incyte Corporation
Email me when this page changes — new trials, changes of phase or status, and results as they are posted.
No mail is going out yet — your address is recorded now, used for nothing else, and never shared.
Thanks — your request is recorded. No mail is sent yet.
That did not work. Check the address and try again.
Recruiting Phase 3
Recently started
Results recently posted
Pipeline
Phase by status
| Phase | Recruiting | Not yet | Active | Completed | Terminated | Withdrawn | Approved for marketing | Available | No longer available | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Phase 1 | 11 | 1 | 5 | 46 | 14 | 1 | — | — | — | 78 |
| Phase 1/2 | — | — | 3 | 11 | 20 | — | — | — | — | 34 |
| Phase 2 | 6 | 1 | 6 | 55 | 22 | 3 | — | — | — | 93 |
| Phase 2/3 | — | — | — | 1 | 1 | — | — | — | — | 2 |
| Phase 3 | 9 | 1 | 12 | 24 | 8 | 6 | — | — | — | 60 |
| Phase 4 | — | — | — | — | 1 | — | — | — | — | 1 |
| Unknown | 3 | — | — | 4 | — | — | 3 | 2 | 5 | 17 |
Trials started per year
Conditions studied, by phase
| Condition | Phase 1 | Phase 1/2 | Phase 2 | Phase 2/3 | Phase 3 | Phase 4 | Unknown | Total |
|---|---|---|---|---|---|---|---|---|
| Myeloproliferative Disorders | 6 | 4 | 10 | — | 3 | — | 2 | 25 |
| Carcinoma, Non-Small-Cell Lung | 6 | 6 | 9 | — | 3 | — | — | 24 |
| Primary Myelofibrosis | 7 | 5 | 7 | — | 3 | — | 1 | 23 |
| Colorectal Neoplasms | 8 | 6 | 3 | — | 1 | — | — | 18 |
| Dermatitis, Atopic | 3 | — | 3 | — | 6 | 1 | 3 | 16 |
| Melanoma | 4 | 6 | 3 | — | 1 | — | — | 14 |
| Lymphoma | 2 | 6 | 4 | — | — | — | 1 | 13 |
| Lymphoma, Large B-Cell, Diffuse | 4 | 4 | 1 | 1 | 2 | — | 1 | 13 |
| Neoplasm Metastasis | 5 | 3 | 4 | — | 1 | — | — | 13 |
| Skin Diseases | 1 | — | 6 | — | 6 | — | — | 13 |
Most active sponsors
| # | Sponsor | Trials | Phase 3 |
|---|---|---|---|
| 1 | Incyte Corporation | 285 | 62 |
Frequent collaborators
| # | Collaborator | Trials |
|---|---|---|
| 1 | Merck Sharp & Dohme LLC | 8 |
| 2 | Bristol-Myers Squibb | 3 |
| 3 | GOG Foundation | 3 |
| 4 | AstraZeneca | 2 |
| 5 | ENGOT Foundation | 2 |
| 6 | Novartis Pharmaceuticals | 2 |
| 7 | Blood and Marrow Transplant Clinical Trials Network | 1 |
| 8 | Children's Oncology Group | 1 |
| 9 | European Network of Gynaecological Oncological Trial Groups (ENGOT) | 1 |
| 10 | Genentech, Inc. | 1 |
Most studied interventions
| # | Intervention | Trials |
|---|---|---|
| 1 | ruxolitinib | 60 |
| 2 | itacitinib | 28 |
| 3 | INCB039110 | 27 |
| 4 | parsaclisib | 26 |
| 5 | epacadostat | 24 |
| 6 | pembrolizumab | 16 |
| 7 | pemigatinib | 14 |
| 8 | Gemcitabine | 13 |
| 9 | Cisplatin | 11 |
| 10 | Carboplatin | 10 |
Terminations
Stated reasons
Reasons are grouped from the sponsor's own wording with a rule-based classifier; the original text is shown below.
Recently stopped
| Trial | Status | Stated reason | Stopped |
|---|---|---|---|
| NCT06873789 Terminated | Terminated | This was a strategic business decision. There were no safety concerns contributing to this decision. | 2026-07-29 |
| NCT04640025 Terminated | Terminated | The decision to close the study was made due to the expiration of remaining drug supply. | 2026-05-11 |
| NCT07039929 Terminated | Terminated | Strategic Business Decision | 2025-10-11 |
| NCT03522142 Terminated | Terminated | The study was terminated after careful review of the overall clinical activity of this compound and a lack of robust efficacy. The study closure is not based on safety concerns. | 2025-09-10 |
| NCT06039384 Terminated | Terminated | This was a strategic business decision. There were no safety concerns contributing to this decision. | 2025-07-11 |
| NCT03656536 Terminated | Terminated | The study was terminated due to lack of enrollment resulting from a change in the standard of care for the first-line treatment of patients with cholangiocarcinoma. There were no safety concerns that contributed to this decision. | 2025-07-07 |
| NCT05949632 Terminated | Terminated | This was a strategic business decision. There were no safety concerns contributing to this decision. | 2025-06-06 |
| NCT05696392 Terminated | Terminated | The study was terminated due to lack of enrollment. | 2025-01-22 |
| NCT05267106 Terminated | Terminated | Recruitment ceased after a pre-planned futility interim analysis indicated a low probability to confer a clinically meaningful improvement in objective response when compared to currently available therapies. There were no safety related concerns. | 2024-12-17 |
| NCT04551066 Terminated | Terminated | The study was terminated due to futility. | 2024-11-25 |
Evidence
- Results reported
- 89.4%126 of 141 completed
- Published
- 2.1%3 of 141 completed
- Primary endpoint met
- 64.1%50 of 78 analyses
- Median months to report
- 12
Documents disclosed
Trial profile
- Median enrollment
- 73
- Median duration
- 33months
- Countries
- 57
- Study sites
- 7210
Who is enrolled
Median enrollment by phase
- Phase 1
- 46
- Phase 1/2
- 60
- Phase 2
- 64
- Phase 2/3
- 304
- Phase 3
- 309
- Phase 4
- 47
- Unknown
- 1469
Where trials run
Busiest cities
| # | City | Country | Trials |
|---|---|---|---|
| 1 | New York | United States | 101 |
| 2 | Los Angeles | United States | 90 |
| 3 | Madrid | Spain | 85 |
| 4 | Houston | United States | 83 |
| 5 | Barcelona | Spain | 77 |
| 6 | San Antonio | United States | 70 |
| 7 | Milan | Italy | 68 |
| 8 | Nashville | United States | 67 |
| 9 | Boston | United States | 64 |
| 10 | London | United Kingdom | 63 |